Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Caplin Point Laboratories Limited ( (IN:CAPLIPOINT) ).
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited, has received USFDA approval for its Acetaminophen Injection in single-dose infusion bags. This approval marks a significant milestone for Caplin Steriles, allowing it to offer a generic equivalent of a drug with substantial market sales in the US, potentially enhancing its market position and expanding its product offerings in the US pharmaceutical market.
More about Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is a rapidly expanding pharmaceutical company that primarily serves the emerging markets of Latin America and Africa. The company is known for its state-of-the-art manufacturing facilities that produce a wide range of finished dosage forms. Caplin Point has been recognized for its consistent growth in cash flows, profitability, and revenues over the past 15 years and has been featured on Forbes’ ‘Asia’s 200 Best Under a Billion’ list multiple times.
Average Trading Volume: 5,145
Technical Sentiment Signal: Buy
Current Market Cap: 149.2B INR
For a thorough assessment of CAPLIPOINT stock, go to TipRanks’ Stock Analysis page.